HOME >> MEDICINE >> NEWS
ARICEPT significantly improves cognition, daily living over Reminyl in Alzheimers patients

GENEVA, SWITZERLAND (4 APRIL 2002) - Results from the first head-to-head study comparing ARICEPT (donepezil HCl tablets) and Reminyl (galantamine HBr tablets) demonstrated significantly greater improvements in cognition and activities of daily living (ADLs) in mild to moderate Alzheimer's disease (AD) patients treated with ARICEPT vs. Reminyl. ARICEPT-treated patients showed significant benefit over patients receiving Reminyl as measured by the modified 13-item Alzheimer's Disease Assessment Scale-cognitive subscale (modified ADAS-cog), achieved significant improvements on the Mini-Mental State Examination (MMSE), and had significantly greater improvements in ADLs, as measured by the Disability Assessment for Dementia (DAD) scale total score. The study was primarily designed to evaluate safety and tolerability. The first-ever presentation of these data took place at the 7th International Geneva/Springfield Symposium on Advances in Alzheimer Therapy (AAT) in Geneva, Switzerland.

"By comparing two available Alzheimer's disease medications, physicians now have clinical evidence that will help them prescribe the most appropriate treatment for their patients," said study investigator Roy Jones, MD, Research Institute for the Care of the Elderly, St Martin's Hospital, Bath, United Kingdom. "This three month study is encouraging news for mild to moderate Alzheimer's disease patients currently on ARICEPT, as well as those who have yet to initiate treatment." The 12-week, multinational (United Kingdom, Finland, Norway and Germany), head-to-head, randomized open-label study was designed primarily to evaluate the safety and tolerability of ARICEPT (n= 64) and Reminyl (n= 56) in 120 patients with possible or probable mild to moderate Alzheimer's disease. The study also investigated the effects of both treatments on cognition and ADLs, such as meal preparation and finance and correspondence. Trained raters who were blinded to study medication and trial results admin
'"/>


4-Apr-2002


Page: 1 2 3 4

Related medicine news :

1. First-of-its-kind study of vascular dementia patients taking ARICEPT presented at AAGP meeting
2. Vascular dementia patients taking ARICEPT show significant treatment benefits in cognition and function
3. ARICEPT better tolerated than Exelon in patients with mild to moderate Alzheimers disease
4. Moving admitted ER patients into inpatient beds faster could significantly increase hospital revenue
5. Gastrointestinal disorders are associated significantly with sleepless nights
6. Landmark survey reveals asthma in children remains significantly out of control in the United States
7. Data suggest ADDERALL XR significantly improved simulated driving in young adults with ADHD
8. Elderly cancer patients are significantly under-represented in cancer clinical trials
9. Generic anti-inflammatory causes significantly fewer GI complications than branded medications
10. Study shows weight-based REBETOL dosing in combination with PEG-INTRON significantly improves ...
11. Radiotherapy + cetuximab significantly improve disease control and survival in head and neck cancer

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/11/2018)... ... October 11, 2018 , ... Four weeks ... to manipulation,” warns former U.S. Department of Homeland Security deputy assistant secretary Paul ... How We Can Stop it. , Pointing to the ability of Russian hackers ...
(Date:10/6/2018)... , ... October 06, 2018 , ... ... for healthcare treatment professionals who treat the full spectrum of eating disorders (ED), ... organization’s Presidents Council. , “As with each of our Presidents Council members, it ...
(Date:10/5/2018)... ... October 05, 2018 , ... Shofner Vision ... surgery to patients residing in middle Tennessee and surrounding areas. Recognized by his ... States, Dr. Stewart Shofner has performed over 40,000 LASIK procedures and ...
(Date:10/5/2018)... ... ... The American Orthopaedic Society for Sports Medicine ( AOSSM ) is proud ... passage of the Sports Medicine Licensure Clarity Act (H.R.302) which was signed into law ... legal protection for traveling team physicians and safeguards injured athletes’ timely access to the ...
(Date:10/5/2018)... ... October 05, 2018 , ... ... healthcare professionals through an all-digital platform, today announced the launch of ... , "This is a unique and easy-to-use educational tool for all rheumatologists,” ...
Breaking Medicine News(10 mins):
(Date:10/13/2018)... ... October 13, 2018 , ... As news hits that ... cent over the next five years, from $3200 million in 2017 to $7170 million ... could even help drive this growth further. This news comes hot on the heels ...
(Date:10/11/2018)... ... October 11, 2018 , ... In the last four months it has ... families and allowance of six more in USA, China and Japan from three other ... MRI safety and security products. , The patents assigned from QinetiQ include US 7113092, ...
(Date:10/6/2018)... OBISPO, Calif. (PRWEB) , ... October 06, 2018 , ... ... surgery or an injury. Carol Rowsemitt, PhD, RN, FNP-C, a San Luis Obispo ... losing weight. She understands this better than most dietitians. , Rowsemitt specializes in helping ...
Breaking Medicine Technology:
Cached News: